RIGL
Rigel Pharmaceuticals Inc
46.10$
-3.5%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.6% | +7.9% | +1.5% | +8.6% | +17.6% | +7.3% | +17.5% | +17.3% | +111.8% | -1.7% | +3.3% | |
| – | +4.5% | -6.8% | +2.4% | +12.4% | +26.9% | +8.5% | +19.7% | +22.5% | +11.7% | -2.6% | -20.7% | |
| – | -27.8% | -22.0% | +41.0% | +43.4% | +9.8% | -19.4% | +16.8% | -9.1% | -16.4% | -39.8% | +149.1% | |
| – | -8.7% | -13.0% | -0.9% | +24.5% | +26.5% | -0.3% | +40.6% | +26.5% | +13.0% | -5.3% | -35.0% | |
| – | +29.7% | -9.9% | +5.1% | +5.8% | +36.1% | -0.2% | -3.9% | +15.1% | +12.7% | -3.5% | +12.2% | |
| – | -9.7% | +19.1% | +22.5% | -40.6% | +25.5% | -22.4% | +123.7% | +97.7% | -44.2% | +1.3% | +23.3% | |
| – | -1.9% | +108.0% | -2.0% | -2.1% | -2.1% | -2.2% | -2.2% | -2.3% | -2.3% | -2.4% | +288.6% | |
| – | -0.9% | +8.4% | +0.1% | -2.7% | +4.3% | -2.0% | -20.7% | +0.1% | -2.3% | -14.3% | -8.9% | |
| – | +10.3% | +37.4% | -19.9% | -7.4% | +16.5% | +5.3% | +30.0% | +9.0% | +5.1% | -9.8% | +6.6% | |
| – | +1,077.0% | +95.5% | -95.9% | -27.1% | +1,521.7% | +102.1% | +49.8% | +32.7% | +0.2% | +0.2% | +30.8% | |
| – | -10.7% | +29.9% | -33.9% | -37.8% | -12.5% | +18.4% | +84.4% | -47.2% | +87.0% | -37.6% | -10.6% | |
| – | -12.2% | -14.2% | +32.9% | +0.1% | -12.3% | -14.3% | -16.6% | -20.0% | -25.0% | -33.3% | – | |
| – | – | – | – | – | – | +464.7% | +341.3% | +43.5% | +232.9% | +2.2% | +6.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.4% | +0.2% | +0.6% | +1.9% | +1.0% | 0.0% | +5.5% | -1.6% | +4.5% | -0.6% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.